The Latin America, Middle East and Africa Cancer Biomarkers Market is expected to witness market growth of 23.4% CAGR during the forecast period (2022-2028).
In oncology, biomarkers are substances secreted by a tumor or a distinct human body reaction that indicate the existence of cancer. Using diverse genomes and proteomics technologies, biomarkers enable early cancer detection and ease high-speed non-invasive diagnosis. Biomarkers are employed in a variety of applications, including cancer diagnosis, medication research, prognostics, and customized medicine. In addition, the growing demand for biomarkers in medication research and development for personalized medicine is propelling the Market forward.
Research and development in cancer biomarkers is aided by funding from various government & private organizations. Increasing investment in cancer biomarker research and development is a priority for a number of government and corporate organizations. This is due to the rising global incidence and prevalence of cancer.
Cancer is a significant public health concern that affects people all across the world. It is one of the top causes of death in a number of regions, depending on individual differences. Socioeconomic, ethnic, racial, and cultural characteristics differ across low and high-income countries, resulting in inequities.
According to data from the International Agency for Research on Cancer's (IARC) GLOBOCAN 2018 database, the estimated results of 36 cancer types available from 47 countries in WHO's African region (AFRO) revealed that 811,200 new cancer cases (4.5% of the total world) and 534,000 cancer deaths (7.3% of the total world) were reported in AFRO countries in 2018. The estimated cancer burden in AFRO countries is mostly due to breast cancer, which accounts for 27.7% of all cancer cases, trailed by cervical cancer, which accounts for 19.6% of all cases. When taken as a whole, this is the most prevalent in African girls.
The Brazil Market dominated the LAMEA Cancer Biomarkers Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $765.9 million by 2028. The Argentina Market is estimated to grow at a CAGR of 24.1% during (2022-2028). Additionally, The UAE Market is expected to showcase a CAGR of 23.1% during (2022-2028).
Based on Profiling Technologies, the Market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, and Cytogenetics. Based on Application, the Market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Others. Based on Type, the Market is segmented into Protein, Genetic, and Others. Based on Cancer Type, the Market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma & Leukemia, Kidney & Bladder Cancer, Non-Hodgkin's Lymphoma, Prostate Cancer, and Others. Based on countries, the Market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.
By Profiling Technologies
By Country
In oncology, biomarkers are substances secreted by a tumor or a distinct human body reaction that indicate the existence of cancer. Using diverse genomes and proteomics technologies, biomarkers enable early cancer detection and ease high-speed non-invasive diagnosis. Biomarkers are employed in a variety of applications, including cancer diagnosis, medication research, prognostics, and customized medicine. In addition, the growing demand for biomarkers in medication research and development for personalized medicine is propelling the Market forward.
Research and development in cancer biomarkers is aided by funding from various government & private organizations. Increasing investment in cancer biomarker research and development is a priority for a number of government and corporate organizations. This is due to the rising global incidence and prevalence of cancer.
Cancer is a significant public health concern that affects people all across the world. It is one of the top causes of death in a number of regions, depending on individual differences. Socioeconomic, ethnic, racial, and cultural characteristics differ across low and high-income countries, resulting in inequities.
According to data from the International Agency for Research on Cancer's (IARC) GLOBOCAN 2018 database, the estimated results of 36 cancer types available from 47 countries in WHO's African region (AFRO) revealed that 811,200 new cancer cases (4.5% of the total world) and 534,000 cancer deaths (7.3% of the total world) were reported in AFRO countries in 2018. The estimated cancer burden in AFRO countries is mostly due to breast cancer, which accounts for 27.7% of all cancer cases, trailed by cervical cancer, which accounts for 19.6% of all cases. When taken as a whole, this is the most prevalent in African girls.
The Brazil Market dominated the LAMEA Cancer Biomarkers Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $765.9 million by 2028. The Argentina Market is estimated to grow at a CAGR of 24.1% during (2022-2028). Additionally, The UAE Market is expected to showcase a CAGR of 23.1% during (2022-2028).
Based on Profiling Technologies, the Market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, and Cytogenetics. Based on Application, the Market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Others. Based on Type, the Market is segmented into Protein, Genetic, and Others. Based on Cancer Type, the Market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma & Leukemia, Kidney & Bladder Cancer, Non-Hodgkin's Lymphoma, Prostate Cancer, and Others. Based on countries, the Market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.
Scope of the Study
Market Segments Covered in the Report:
By Profiling Technologies
- Omics Technologies
- Imaging Technologies
- Immunoassay
- Bioinformatics
- Cytogenetics
- Diagnostics
- Research & Development
- Prognostics
- Risk Assessment
- Others
- Protein
- Genetic
- Others
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Thyroid Cancer
- Melanoma & Leukemia
- Kidney & Bladder Cancer
- Non-Hodgkin's Lymphoma
- Prostate Cancer
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- BioMérieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Merck & Co., Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Cancer Biomarkers Market by Profiling Technologies
Chapter 5. LAMEA Cancer Biomarkers Market by Application
Chapter 6. LAMEA Cancer Biomarkers Market by Type
Chapter 7. LAMEA Cancer Biomarkers Market by Cancer Type
Chapter 8. LAMEA Cancer Biomarkers Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- BioMérieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Merck & Co., Inc.
Methodology
LOADING...
